Structure-dependent inhibition of gelatinases by dietary antioxidants in rat astrocytes and sera of multiple sclerosis patients

Neurochemical Research

Volumn 36, Issue 3, 2011, Pages 518-527

  Liuzzi, Grazia Maria ^a   Latronico, Tiziana ^a   Branà, Maria Teresa ^a   Gramegna, Pasqua ^a   Coniglio, Maria Gabriella ^b   Rossano, Rocco ^c   Larocca, Marilena ^c   Riccio, Paolo ^c,d  

^a UNIVERSITY OF BARI   (Italy)

^b MADONNA DELLE GRAZIE HOSPITAL   (Italy)

^c UNIVERSITY OF BASILICATA   (Italy)

^d NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Astrocytes; Inflammation; Matrix metalloproteinases; Pathogenesis of multiple sclerosis; Polyphenols; Zymography

Indexed keywords

EPICATECHIN; GELATINASE A; GELATINASE B; HYDROXYTYROSOL; MESSENGER RNA; QUERCETIN; RESVERATROL; TYROSOL;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIOXIDANTS; ASTROCYTES; CELLS, CULTURED; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HUMANS; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MOLECULAR STRUCTURE; MULTIPLE SCLEROSIS; PHENOLS; POLYPHENOLS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS; RICE STRIPE VIRUS;

EID: 79954415157     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-010-0373-2     Document Type: Article

References (56)

1. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372: 1502-1517.
2. World Health Organisation (WHO) and Multiple Sclerosis International Federation (MSIF) Atlas: multiple sclerosis resources in the world 2008, Geneva. (www.who.int/entity/mental-health/neurology/Atlas-MS-WEB).
3. Ebers GC, Sadovnick AD (1994) The role of genetic factors in multiple sclerosis susceptibility. J Neuroimmunol 54:1-17. (Pubitemid 24312617)
4. Ascherio A, Munger K (2008) Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 28:17-28. (Pubitemid 351273081)
5. Lauer K (2010) Environmental risk factors in multiple sclerosis. Expert Rev Neurother 10:421-440.
6. Lassmann H, Brück W, Lucchinetti CF (2007) The immunopathology of multiple sclerosis: an overview. Brain Pathol 17: 210-218. (Pubitemid 46466140)
7. McFarland HF, Martin R (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 8:913-919. (Pubitemid 47300005)
8. Gilgun-Sherki Y, Melamed E, Offen D (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2:261-268. (Pubitemid 38387142)
9. Steiner J, Haughey N, Li W et al (2006) Oxidative stress and therapeutic approaches in HIV dementia. Antioxid Redox Signal 8:2089-2100. (Pubitemid 46489633)
10. Pun PB, Lu J, Moochhala S (2009) Involvement of ROS in BBB dysfunction. Free Radic Res 43:348-364.
11. Wang JY, Wen LL, Huang YN et al (2006) Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of gliamediated inflammation. Curr Pharm Des 12:3521-3533.
12. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57-69. (Pubitemid 46011999)
13. Liu B, Hong JS (2003) Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304:1-7 Review. (Pubitemid 36008905)
14. McGeer PL, Yasojima K, McGeer EG (2001) Inflammation in Parkinson's disease. Adv Neurol 86:83-89.
15. Bélanger M, Magistretti PJ (2009) The role of astroglia in neuroprotection. Dialogues Clin Neurosci 11:281-295.
16. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839. (Pubitemid 36542523)
17. Rosenberg GA (2002) Matrix metalloproteinases in neuroinflammation. Glia 39:279-291.
18. Rosenberg GA, Dencoff JE, Correa N Jr et al (1996) Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46:1626-1632. (Pubitemid 26185784)
19. Agrawal SM, Lau L, Yong VW (2008) MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol 19:42-51. (Pubitemid 350235982)
20. Liuzzi GM, Trojano M, Fanelli M et al (2002) Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 8:222-228. (Pubitemid 34654058)
21. Muroski ME, Roycik MD, Newcomer RG et al (2008) Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol 9:34-46. (Pubitemid 351266968)
22. Yong VW, Zabad RK, Agrawal S et al (2007) Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci 259:79-84. (Pubitemid 47031205)
23. Stuve O, Dooley NP, Uhm JH et al (1996) Interferon b-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40:853-863. (Pubitemid 27044603)
24. Trojano M, Avolio C, Liuzzi GM et al (1999) Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 53:1402-1408. (Pubitemid 29491928)
25. Liuzzi GM, Latronico T, Fasano A et al (2004) Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler 10:290-297. (Pubitemid 38807457)
26. Liuzzi GM, Latronico T, Rossano R et al (2007) Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells-implications for complementary multiple sclerosis treatment. Neurochem Res 32:2184-2193. (Pubitemid 350059862)
27. Bravo L (1998) Polyphenols: chemistry, dietary sources, metabolism and nutritional significance. Nutr Rev 56:317-333. (Pubitemid 28532456)
28. Boots AW, Haenen GR, Bast A (2008) Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 585: 325-337.
29. Friedman M (2007) Overview of antibacterial, antitoxin, antiviral, and antifungal activities of tea flavonoids and teas. Mol Nutr Food Res 51:116-134. (Pubitemid 46144767)
30. Das S, Das DK (2007) Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets 6:168-173. (Pubitemid 47455785)
31. Shakibaei M, Harikumar KB, Aggarwal BB (2009) Resveratrol addiction: to die or not to die. Mol Nutr Food Res 53:115-128.
32. Rietjens SJ, Bast A, Haenen GRMM (2007) New insights into controversies on the antioxidant potential of the olive oil antioxidant hydroxytyrosol. J Agric Food Chem 55:7609-7614. (Pubitemid 47492322)
33. Zheng LT, Ryu GM, Kwon BM et al (2008) Anti-inflammatory effects of catechols in lipopolysaccharide-stimulated microglia cells: inhibition of microglial neurotoxicity. Eur J Pharmacol 588:106-113.
34. Kanashiro A, Souza JG, Kabeya LM et al (2007) Elastase release by stimulated neutrophils inhibited by flavonoids: importance of the catechol group. Z Naturforsch 62:357-361. (Pubitemid 47605218)
35. Nakajima K, Hamanoue M, Shimojo M et al (1989) Characterization of microglia isolated from a primary culture of embryonic rat brain by a simplified method. Biomed Res 10:411-423. (Pubitemid 20172790)
36. McCarthy KD, De Vellis J (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85:890-902. (Pubitemid 10007455)
37. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63. (Pubitemid 14203433)
38. Heussen C, Dowdle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102:196-202. (Pubitemid 10099499)
39. Liuzzi GM, Mastroianni CM, Latronico T et al (2004) Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain 127:398-407. (Pubitemid 38160324)
40. Gonsette RE (2008) Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis? Mult Scler 14:22-34. (Pubitemid 351541394)
41. Van der Goes A, Wouters D, Van der Pol SM et al (2001) Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier in vitro. FASEB J 15:1852-1854.
42. Smith KJ, Kapoor R, Felts PA (1999) Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9:69-92. (Pubitemid 29056521)
43. Smith KJ, Hall SM (2001) Factors directly affecting impulse transmission in inflammatory demyelinating disease: recent advances in our understanding. Curr Opin Neurol 14:289-298. (Pubitemid 32510591)
44. Nelson KK, Melendez JA (2004) Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 37:768-784. (Pubitemid 39078549)
45. Prasad S, Phromnoi K, Yadav V et al (2010) Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med 76:1044-1063.
46. Van den Steen PE, Dubois B, Nelissen I et al (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase- 9 (MMP-9). Crit Rev Biochem Mol Biol 37:375-536. (Pubitemid 36071972)
47. Youdim KA, Qaiser MZ, Begley DJ et al (2004) Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med 36:592-604. (Pubitemid 38230176)
48. Offen D, Gilgun-Sherki Y, Barhum Y et al (2004) A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem 89:1241-1251. (Pubitemid 38715842)
49. Mandel S, Anit T, Reznichenko L et al (2006) Green tea catechins as brain permeable, natural iron chelators antioxidants for the treatment of neurodegenerative disorders. Mol Nutr Food Res 50:229-234. (Pubitemid 43325663)
50. Li YT, Shen F, Liu BH et al (2003) Resveratrol inhibits matrix metalloproteinase-9 transcription in U937 cells. Acta Pharmacol Sin 24:1167-1171.
51. Sun C, Hu Y, Liu X et al (2006) Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet 165:9-19. (Pubitemid 43254647)
52. Wang L, Tu YC, Lian TW et al (2006) Distinctive antioxidant and antiinflammatory effects of flavonols. J Agric Food Chem 54:9798-9804. (Pubitemid 46158973)
53. Silberberg M, Morand C, Mathevon T (2006) The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. Eur J Nutr 45:88-96. (Pubitemid 43345201)
54. Archivio MD, Filesi C, Di-Benedetto R et al (2007) Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanità 43: 348-361.
55. La-Porte C, Voduc N, Zhang G, Seguin I et al (2010) Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 49:449-454.
56. Calamini B, Ratia K, Malkowski MG et al (2010) Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 429:273-282.